Cargando…
Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent EGFR exon 19 deletion and TP53 comutation: a case report
BACKGROUND: Aumolertinib (HS-10296), a 3rd-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been shown to have efficacy in treating tumors harboring EGFR sensitive mutations: EGFR in-frame deletions or insertions within exon 19 deletion (19Del) and the exon 21...
Autores principales: | Qin, Zhiquan, Zhang, Hang, Yan, Peiyuan, Yu, Lili, Hong, Chaojin, Calvetti, Lorenzo, Passaro, Antonio, Araujo, Antonio, Chen, Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407486/ https://www.ncbi.nlm.nih.gov/pubmed/37559636 http://dx.doi.org/10.21037/jtd-23-841 |
Ejemplares similares
-
First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up
por: Jia, Ziqi, et al.
Publicado: (2020) -
Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report
por: Wu, Han, et al.
Publicado: (2022) -
Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q
por: Song, Yang, et al.
Publicado: (2020) -
A new method for accurately localizing and resecting pulmonary nodules
por: Wang, Gongming, et al.
Publicado: (2020) -
Pectus excavatum requiring temporary pacemaker implantation before Nuss procedure: a case report
por: Wang, Gebang, et al.
Publicado: (2020)